Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716))

P. Y. Kwo; E. J. Lawitz; J. McCone

doi:10.1016/S0140-6736(10)61881-8

Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716))

P. Y. Kwo, E. J. Lawitz, J. McCone

Producción científica: Comment/debate › revisión exhaustiva

Idioma original	English (US)
Páginas (desde-hasta)	1224
Número de páginas	1
Publicación	The Lancet
Volumen	376
N.º	9748
DOI	https://doi.org/10.1016/S0140-6736(10)61881-8
Estado	Published - oct 9 2010
Publicado de forma externa	Sí

ASJC Scopus subject areas

General Medicine

Acceder al documento

10.1016/S0140-6736(10)61881-8

Otros archivos y enlaces

Citar esto

Kwo, P. Y., Lawitz, E. J., & McCone, J. (2010). Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716)). The Lancet, 376(9748), 1224. https://doi.org/10.1016/S0140-6736(10)61881-8

Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716)). / Kwo, P. Y.; Lawitz, E. J.; McCone, J.
En: The Lancet, Vol. 376, N.º 9748, 09.10.2010, p. 1224.

Producción científica: Comment/debate › revisión exhaustiva

Kwo, PY, Lawitz, EJ & McCone, J 2010, 'Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716))', The Lancet, vol. 376, n.º 9748, pp. 1224. https://doi.org/10.1016/S0140-6736(10)61881-8

Kwo PY, Lawitz EJ, McCone J. Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716)). The Lancet. 2010 oct 9;376(9748):1224. doi: 10.1016/S0140-6736(10)61881-8

Kwo, P. Y. ; Lawitz, E. J. ; McCone, J. / Erratum : Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716)). En: The Lancet. 2010 ; Vol. 376, N.º 9748. pp. 1224.

@article{0252ca4d5d854d4882ea02744ce03840,

title = "Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716))",

author = "Kwo, {P. Y.} and Lawitz, {E. J.} and J. McCone",

year = "2010",

month = oct,

day = "9",

doi = "10.1016/S0140-6736(10)61881-8",

language = "English (US)",

volume = "376",

pages = "1224",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9748",

}

TY - JOUR

T1 - Erratum

T2 - Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716))

AU - Kwo, P. Y.

AU - Lawitz, E. J.

AU - McCone, J.

PY - 2010/10/9

Y1 - 2010/10/9

UR - http://www.scopus.com/inward/record.url?scp=77957978374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957978374&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)61881-8

DO - 10.1016/S0140-6736(10)61881-8

M3 - Comment/debate

AN - SCOPUS:77957978374

SN - 0140-6736

VL - 376

SP - 1224

JO - The Lancet

JF - The Lancet

IS - 9748

ER -